Brad S. Schneider

Brad S. Schneider, PhD, currently serves as the Board Chair and Chief Executive Officer at Pinpoint Science Inc., where efforts focus on the development of bioelectronic diagnostic devices for public health threats, achieving significant milestones including prototype creation and funding acquisition. In addition, Brad Schneider holds the position of Lead Strategic and Operations Advisor at V4C, aimed at innovating mRNA vaccines for dengue virus, and serves as Managing Principal and Chief Scientist at Etiologic, providing strategic consulting on emerging infectious diseases and biotechnologies. Additional roles include contributing as an Affiliated Expert in Global Health Security at CRDF Global and an Associate Editor for Vector-Borne and Zoonotic Diseases. Brad Schneider has a strong academic background with a Ph.D. in Virology from The University of Texas Medical Branch and a B.S. in Microbiology from the University of Colorado Boulder, alongside extensive experience leading scientific research and fostering collaborative initiatives in global health and disease detection.